Core Insights - ImmunityBio (IBRX) is leveraging a persistent Bacillus Calmette-Guérin (BCG) shortage to enhance the adoption of its lead immunotherapy, Anktiva, particularly in non-muscle invasive bladder cancer (NMIBC) [1][10] - The company is set to reach significant milestones in 2026 that will clarify the pace of adoption and its ability to expand internationally [1] BCG Shortage Dynamics - The ongoing BCG shortage is a structural catalyst that is reshaping how urology practices source and sequence therapies, creating unusual demand dynamics [2] - ImmunityBio is expanding access pathways to keep urologists engaged and reinforce Anktiva's role in NMIBC treatment [3] Expanded Access Program - The FDA-authorized expanded access program for recombinant BCG has scaled to approximately 100 active sites and treated over 500 patients by January 2026 [4][10] - The program's operational throughput indicates significant delivery in a constrained supply environment, supporting broader urology engagement over time [5] Regulatory and Clinical Milestones - A scheduled FDA meeting in March 2026 will address the regulatory pathway for the recombinant BCG program, serving as a key event for investors to track [7] - ImmunityBio's NMIBC data shows a complete response rate of 71% for Anktiva plus BCG in BCG-unresponsive carcinoma in situ, with durability extending beyond 53 months [8][9] International Expansion - The European Commission granted conditional marketing authorization for Anktiva plus BCG in February 2026, expanding the commercial landscape beyond the U.S. [12] - The company's strategy includes country-by-country reimbursement, with Germany expected to commercialize first in 2026 [13] Execution and Scaling Tools - As ImmunityBio expands its programs and geographies, it is utilizing scaling tools like the NANT Leonardo AI-robotic platform to automate production and lower costs [14] - The askIB AI initiative aims to accelerate decision-making across research, manufacturing, and operations as the company scales [15]